Skip to main content
Top
Published in: Calcified Tissue International 5/2013

01-11-2013 | Original Research

Genetic Association Study of Dickkopf-1 and Sclerostin Genes with Paget Disease of Bone

Authors: Mariejka Beauregard, Edith Gagnon, Sabrina Guay-Bélanger, Ethel S. Siris, Jean Morissette, Jacques P. Brown, Laëtitia Michou

Published in: Calcified Tissue International | Issue 5/2013

Login to get access

Abstract

Increased expression of DKK1 gene was reported in pagetic osteoblasts and stromal cells, and increased serum levels of DKK1 and SOST proteins were reported in patients with Paget disease of bone (PDB). This study aimed at identifying rare genetic variants of the DKK1 and SOST genes and at testing for genetic association with PDB in the French-Canadian population. Exons, promoters, and exon–intron junctions of these genes were sequenced in patients with PDB and healthy controls. An association study of Tag SNPs of both genes was also performed in 239 pagetic patients and 297 healthy individuals. Three rare variants were identified in this study, all located in the DKK1 gene: one variant in the second exon leading to alteration in a highly conserved amino acid (p.R120L), one in the 5′-untranslated region (−50 C/A), and one in a splice site of intron 1 (IVS1 184 T/C), although none of these rare variants were associated with PDB. A genetic association of a Tag SNP of the DKK1 gene was found: the G allele of rs1569198 was significantly decreased in patients in comparison to controls (42 vs. 49 %, uncorrected P = 0.03, OR = 0.77, 95 % CI 0.61–0.98). In conclusion, this study identified three rare genetic variants in DKK1 in the French-Canadian population. In addition, a weak genetic association of a common variant of DKK1, rs1569198, which is located on a predicted new acceptor site for splicing of this gene, was observed in PDB, whereas no rare variant or genetic association was found in the SOST gene.
Literature
1.
go back to reference van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471PubMedCrossRef van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471PubMedCrossRef
2.
go back to reference Goode A, Layfield R (2010) Recent advances in understanding the molecular basis of Paget’s disease of bone. J Clin Pathol 63:199–203PubMedCrossRef Goode A, Layfield R (2010) Recent advances in understanding the molecular basis of Paget’s disease of bone. J Clin Pathol 63:199–203PubMedCrossRef
3.
go back to reference Roodman GD, Windle JJ (2005) Paget disease of bone. J Clin Invest 115:200–208PubMed Roodman GD, Windle JJ (2005) Paget disease of bone. J Clin Invest 115:200–208PubMed
4.
go back to reference Laurin N, Brown JP, Morissette J, Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588PubMedCrossRef Laurin N, Brown JP, Morissette J, Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588PubMedCrossRef
5.
go back to reference Morissette J, Laurin N, Brown JP (2006) Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget’s disease of bone. J Bone Miner Res 21(Suppl 2):P38–P44PubMedCrossRef Morissette J, Laurin N, Brown JP (2006) Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget’s disease of bone. J Bone Miner Res 21(Suppl 2):P38–P44PubMedCrossRef
6.
go back to reference Chung PY, Van Hul W (2012) Paget’s disease of bone: evidence for complex pathogenetic interactions. Semin Arthritis Rheum 41:619–641PubMedCrossRef Chung PY, Van Hul W (2012) Paget’s disease of bone: evidence for complex pathogenetic interactions. Semin Arthritis Rheum 41:619–641PubMedCrossRef
7.
go back to reference Hocking LJ, Lucas GJ, Daroszewska A, Cundy T, Nicholson GC, Donath J, Walsh JP, Finlayson C, Cavey JR, Ciani B, Sheppard PW, Searle MS, Layfield R, Ralston SH (2004) Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 19:1122–1127PubMedCrossRef Hocking LJ, Lucas GJ, Daroszewska A, Cundy T, Nicholson GC, Donath J, Walsh JP, Finlayson C, Cavey JR, Ciani B, Sheppard PW, Searle MS, Layfield R, Ralston SH (2004) Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 19:1122–1127PubMedCrossRef
8.
go back to reference Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333:2–13PubMedCrossRef Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333:2–13PubMedCrossRef
9.
go back to reference Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, Dunlop MG, Fraser WD, Hooper MJ, Isaia G, Nicholson GC, del Pino MontesJ, Gonzalez-Sarmiento R, di Stefano M, Tenesa A, Walsh JP, Ralston SH (2010) Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone. Nat Genet 42:520–524PubMedCrossRef Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, Dunlop MG, Fraser WD, Hooper MJ, Isaia G, Nicholson GC, del Pino MontesJ, Gonzalez-Sarmiento R, di Stefano M, Tenesa A, Walsh JP, Ralston SH (2010) Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone. Nat Genet 42:520–524PubMedCrossRef
10.
go back to reference Albagha OM, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML, Cundy T, Chung PY, Dargie R, Devogelaer JP, Falchetti A, Fraser WD, Gennari L, Gianfrancesco F, Hooper MJ, Van Hul W, Isaia G, Nicholson GC, Nuti R, Papapoulos S, del Montes P, Ratajczak T, Rea SL, Rendina D, Gonzalez-Sarmiento R, Di Stefano M, Ward LC, Walsh JP, Ralston SH (2011) Genome-wide association identifies three new susceptibility loci for Paget’s disease of bone. Nat Genet 43:685–689PubMedCrossRef Albagha OM, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML, Cundy T, Chung PY, Dargie R, Devogelaer JP, Falchetti A, Fraser WD, Gennari L, Gianfrancesco F, Hooper MJ, Van Hul W, Isaia G, Nicholson GC, Nuti R, Papapoulos S, del Montes P, Ratajczak T, Rea SL, Rendina D, Gonzalez-Sarmiento R, Di Stefano M, Ward LC, Walsh JP, Ralston SH (2011) Genome-wide association identifies three new susceptibility loci for Paget’s disease of bone. Nat Genet 43:685–689PubMedCrossRef
11.
go back to reference Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MW (2009) Increased circulating Dickkopf-1 in Paget’s disease of bone. Clin Biochem 42:965–969PubMedCrossRef Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MW (2009) Increased circulating Dickkopf-1 in Paget’s disease of bone. Clin Biochem 42:965–969PubMedCrossRef
13.
go back to reference Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE (2012) Serum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 51:153–157PubMedCrossRef Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE (2012) Serum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 51:153–157PubMedCrossRef
14.
go back to reference Naot D, Bava U, Matthews B, Callon KE, Gamble GD, Black M, Song S, Pitto RP, Cundy T, Cornish J, Reid IR (2007) Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget’s disease of bone. J Bone Miner Res 22:298–309PubMedCrossRef Naot D, Bava U, Matthews B, Callon KE, Gamble GD, Black M, Song S, Pitto RP, Cundy T, Cornish J, Reid IR (2007) Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget’s disease of bone. J Bone Miner Res 22:298–309PubMedCrossRef
15.
go back to reference Costa AG, Bilezikian JP (2012) Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep 10:64–72PubMedCrossRef Costa AG, Bilezikian JP (2012) Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep 10:64–72PubMedCrossRef
16.
go back to reference Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99–107PubMedCrossRef Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99–107PubMedCrossRef
17.
go back to reference Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, Fang Y, van Meurs JB, Britschgi TB, Latham JA, Schatzman RC, Pols HA, Brunkow ME (2004) Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet 75:1032–1045PubMedCrossRef Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, Fang Y, van Meurs JB, Britschgi TB, Latham JA, Schatzman RC, Pols HA, Brunkow ME (2004) Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet 75:1032–1045PubMedCrossRef
18.
go back to reference Frazer KA, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation and its contribution to complex traits. Nat Rev Genet 10:241–251PubMedCrossRef Frazer KA, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation and its contribution to complex traits. Nat Rev Genet 10:241–251PubMedCrossRef
19.
go back to reference Laberge AM (2007) Prevalence and distribution of genetic diseases in Quebec: impact of the past on the present [in French]. Med Sci (Paris) 23:997–1001CrossRef Laberge AM (2007) Prevalence and distribution of genetic diseases in Quebec: impact of the past on the present [in French]. Med Sci (Paris) 23:997–1001CrossRef
20.
go back to reference Bodmer W, Bonilla C (2008) Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 40:695–701PubMedCrossRef Bodmer W, Bonilla C (2008) Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 40:695–701PubMedCrossRef
21.
go back to reference Moreau C, Vezina H, Labuda D (2007) Founder effects and genetic variability in Quebec [in French]. Med Sci (Paris) 23:1008–1013CrossRef Moreau C, Vezina H, Labuda D (2007) Founder effects and genetic variability in Quebec [in French]. Med Sci (Paris) 23:1008–1013CrossRef
22.
go back to reference Laurin N, Brown JP, Lemainque A, Duchesne A, Huot D, Lacourciere Y, Drapeau G, Verreault J, Raymond V, Morissette J (2001) Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528–543PubMedCrossRef Laurin N, Brown JP, Lemainque A, Duchesne A, Huot D, Lacourciere Y, Drapeau G, Verreault J, Raymond V, Morissette J (2001) Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528–543PubMedCrossRef
24.
go back to reference Michou L, Morissette J, Gagnon ER, Marquis A, Dellabadia M, Brown JP, Siris ES (2011) Novel SQSTM1 mutations in patients with Paget’s disease of bone in an unrelated multiethnic American population. Bone 48:456–460PubMedCrossRef Michou L, Morissette J, Gagnon ER, Marquis A, Dellabadia M, Brown JP, Siris ES (2011) Novel SQSTM1 mutations in patients with Paget’s disease of bone in an unrelated multiethnic American population. Bone 48:456–460PubMedCrossRef
25.
go back to reference Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894–3900PubMedCrossRef Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894–3900PubMedCrossRef
26.
go back to reference Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081PubMedCrossRef Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081PubMedCrossRef
27.
go back to reference Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67PubMedCrossRef Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67PubMedCrossRef
28.
go back to reference Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565PubMedCrossRef Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565PubMedCrossRef
29.
go back to reference Korvala J, Loija M, Makitie O, Sochett E, Juppner H, Schnabel D, Mora S, Cole WG, Ala-Kokko L, Mannikko M (2012) Rare variations in WNT3A and DKK1 may predispose carriers to primary osteoporosis. Eur J Med Genet 55:515–519PubMedCrossRef Korvala J, Loija M, Makitie O, Sochett E, Juppner H, Schnabel D, Mora S, Cole WG, Ala-Kokko L, Mannikko M (2012) Rare variations in WNT3A and DKK1 may predispose carriers to primary osteoporosis. Eur J Med Genet 55:515–519PubMedCrossRef
30.
go back to reference Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747–783PubMedCrossRef Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747–783PubMedCrossRef
31.
go back to reference Baron R, Hesse E (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 97:311–325PubMedCrossRef Baron R, Hesse E (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 97:311–325PubMedCrossRef
32.
go back to reference Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13:485–496PubMedCrossRef Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13:485–496PubMedCrossRef
33.
go back to reference McCarthy HS, Marshall MJ (2010) Dickkopf-1 as a potential therapeutic target in Paget’s disease of bone. Expert Opin Ther Targets 14:221–230PubMedCrossRef McCarthy HS, Marshall MJ (2010) Dickkopf-1 as a potential therapeutic target in Paget’s disease of bone. Expert Opin Ther Targets 14:221–230PubMedCrossRef
34.
go back to reference Daoussis D, Andonopoulos AP (2011) The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 41:170–177PubMedCrossRef Daoussis D, Andonopoulos AP (2011) The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 41:170–177PubMedCrossRef
35.
go back to reference Menezes ME, Devine DJ, Shevde LA, Samant RS (2012) Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer 130:1477–1483PubMedCrossRef Menezes ME, Devine DJ, Shevde LA, Samant RS (2012) Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer 130:1477–1483PubMedCrossRef
Metadata
Title
Genetic Association Study of Dickkopf-1 and Sclerostin Genes with Paget Disease of Bone
Authors
Mariejka Beauregard
Edith Gagnon
Sabrina Guay-Bélanger
Ethel S. Siris
Jean Morissette
Jacques P. Brown
Laëtitia Michou
Publication date
01-11-2013
Publisher
Springer US
Published in
Calcified Tissue International / Issue 5/2013
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-013-9762-2

Other articles of this Issue 5/2013

Calcified Tissue International 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine